tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Syndax initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Corinne Johnson initiated coverage of Syndax (SNDX) with a Buy rating and $18 price target implying 100% upside potential. The firm’s positive view is based on the near-term and peak revenue opportunity for Revuforj, Syndax’s wholly-owned lead drug currently approved for the treatment of relapsed/refractory acute myeloid leukemia patients. It estimates peak sales at $1.1B before considering potential use in the frontline setting.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1